GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » Degree of Operating Leverage

CSTL (Castle Biosciences) Degree of Operating Leverage : -2.71 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Castle Biosciences Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Castle Biosciences's Degree of Operating Leverage for the quarter that ended in Dec. 2024 was -2.71. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Castle Biosciences's Degree of Operating Leverage or its related term are showing as below:

CSTL's Degree of Operating Leverage is ranked better than
81.73% of 208 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.89 vs CSTL: -2.71

Castle Biosciences Degree of Operating Leverage Historical Data

The historical data trend for Castle Biosciences's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences Degree of Operating Leverage Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial -8.48 8.55 1.58 -0.28 -2.71

Castle Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.90 -1.34 -1.85 -2.71

Competitive Comparison of Castle Biosciences's Degree of Operating Leverage

For the Diagnostics & Research subindustry, Castle Biosciences's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Castle Biosciences's Degree of Operating Leverage Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's Degree of Operating Leverage falls into.


;
;

Castle Biosciences Degree of Operating Leverage Calculation

Castle Biosciences's Degree of Operating Leverage for the quarter that ended in Dec. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 22.141 (Dec. 2024) / -57.354 (Dec. 2023) - 1 )/( 332.069 (Dec. 2024) / 219.788 (Dec. 2023) - 1 )
=-1.386/0.5109
=-2.71***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Castle Biosciences  (NAS:CSTL) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Castle Biosciences Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Castle Biosciences Business Description

Traded in Other Exchanges
N/A
Address
505 South Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Executives
Derek J Maetzold director, 10 percent owner, officer: Pres. & Chief Exec. Officer 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Frank Stokes officer: Chief Financial Officer C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Tobin W Juvenal officer: Chief Commercial Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Ellen Goldberg director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple director C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff director, 10 percent owner C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii director, 10 percent owner C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p. 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203